The 2018 Trend Specialty Pharma Executives Need to Know
John Cervione, managing partner of Blue Fin Group, explains the top trend impacting executives in the specialty pharma industry.
Speaking at Asembia’s Specialty Pharmacy Summit in Las Vegas, John Cervione, managing partner of Blue Fin Group, explains the top trend impacting executives in the specialty pharma industry.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
